VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | PLATO and immunotherapy trials in anal cancer

David Sebag-Montefiore
ESMO 2019
Colorectal Cancer Gastrointestinal Cancer
CORINTH PLATO Radiotherapy

David Sebag-Montefiore, MRCP, FRCR, Leeds Teaching Hospitals NHS Trust, Leeds, UK, talks about two different trials with strategies for improving outcomes from anal cancer treatment; amending dosage of radiotherapy (PLATO; ISRCTN88455282) and novel agent combinations (CORINTH; NCT04046133). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from David Sebag-Montefiore

2:48
Positive findings of the FOXTROT and RAPIDO trials
David Sebag-Montefiore • 27 Jan 2017
4:30
The UK approach to proton beam therapy clinical trials
David Sebag-Montefiore
3:46
Overview of RAPIDO trial in rectal cancer and FOxTROT trial in colon cancer
David Sebag-Montefiore • 27 Jan 2017
2:29
MRI and MR-LINAC guided radiotherapy
David Sebag-Montefiore • 14 Jun 2018

Related Videos

1:44
EuropaColon survey of the unmet needs of metastatic colorectal cancer patients
Geoffrey Henning
2:31
Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions
Milind Javle
1:20
A promising future for drug development in gastrointestinal cancer
Hani Babiker
2:31
Treatment landscape for HCC
Arndt Vogel

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals